Skip to main content

ASCIA Submissions 2024

ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.

  • ASCIA letter of support for application on the agenda of the July 2024 Pharmaceutical Benefits Advisory Committee (PBAC) meeting: Arexvy® Respiratory Syncytial Virus (RSV) Vaccine application for new NIP listing - Lodged 29 May 2024.
    pdfASCIA letter PBAC AREXVY 2024-05-2952.02 KB

 

Read more …ASCIA Submissions 2024

ASCIA Submissions 2023

ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.

  • ASCIA statement on clinical need to maintain supply of VIT for bees and wasps submitted to Pharmac NZ. Lodged  13 October 2023.
  • ASCIA response to PBS post marketing investigation of the use of omalizumab in chronic spontaneous urticaria. Lodged 19 September 2023.
  • ASCIA submission to ACECQA for approval of ASCIA anaphylaxis e-training for children's education and care. Lodged 1 September 2023. ACECQA approval has been confirmed until  October 2026. Read more here 
  • ASCIA submission in response to the Food Standards Australia New Zealand (FSANZ) call for submissions on Proposal P1028 – Infant Formula.  Submission lodged 13 July 2023.

    pdfASCIA FSANZ P1028 Response July 2023258.66 KB

  • ASCIA submissions on 23 May 2023 in support of two products that are relevant to allergy and immunology, which are on the July 2023 PBAC meeting agenda.

pdfASCIA letter PBAC Avacopan 2023 05 2366.18 KB

 pdfASCIA letter PBAC Dupilumab 2023 05 2367.24 KB

  • ASCIA letter to the Australian Government Department of Health, to provide information to address the Medical Treatment Overseas Program (MTOP) eligibility criteria for thymic transplant, submitted in May 2023.
  • ASCIA has submitted two letters in support of applications for  Medical Research Future Fund (MRFF) research grants, in February and May 2023.
  • ASCIA has submitted two joint letters to the federal Health Minister, the Hon Mark Butler MP, with the National Allergy Council and Allergy & Anaphylaxis Australia regarding the feasibility of pricing for PBS listed products -  venom immunotherapy (May 2023) and medical nutrition products for cow’s milk allergy (April 2023).

Read more …ASCIA Submissions 2023

ASCIA Submissions 2022

ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.

  • ASCIA letter to Medical Services Advisory Committee (MSAC) in support for the Human Genetics Society of Australasia (HGSA) application for services provided by genetic counsellors, submitted on 7 October 2022.
    pdfASCIA supports HGSA MSAC application 20221007
  • ASCIA letter to PBAC supporting the PBS listing of PBS Nucala® (mepolizumab) for treatment of nasal polyps in chronic rhinosinusitis, submitted on 20 September 2022.
    pdfASCIA letter PBAC Nucala 2022092069.78 KB Nucala® (mepolizumab) is now subsidised by the Pharmaceutical Benefits Scheme (PBS) from 1 April 2023 as an add-on treatment for adult patients (18 years and above) with chronic rhinosinusitis with nasal polyps (CRSwNP) that is severe, eosinophilic and recurrent post-surgery.. Read more here
  • Joint letter to the federal Health Minister, the Hon Mark Butler MP, regarding pricing of medical nutrition products for cow’s milk allergy has been sent on behalf of ASCIA, Allergy & Anaphylaxis Australia and the National Allergy Strategy, submitted on 28 July 2022.
  • Letters from ASCIA supporting research project appications to the Medical Research Future Fund (MRFF) have been submitted on 16 February, 3 March, 16 May, 24 June and 1 July 2022.
  • ASCIA letter to the Australian Government Department of Health, to provide information to address the Medical Treatment Overseas Program (MTOP) eligibility criteria about a SCID-ADA patient, in response to a request sent to ASCIA on 8 July 2022. Lodged 20 July 2022. 
  • ASCIA submitted responses to a survey on the Consultation Draft - National Medicines Policy. Lodged 2 March 2022. 
  • Letter from ASCIA in support of the application to the PBAC for PBS listing of Dupixent® (dupilumab) for treatment of severe atopic dermatitis (eczema) in children aged 6-11 years. Lodged 13 January 2022.
    pdfASCIA letter PBAC Dupilumab 2022 01 1352.73 KB
  • ASCIA letter to the Australian Government Department of Health, to provide information to address the Medical Treatment Overseas Program (MTOP) eligibility criteria about a patient with DiGeorge Syndrome and Severe Combined Immune Deficiency (SCID), in response to a request sent to ASCIA on 4 January 2022. Lodged 12 January 2022. 

Read more …ASCIA Submissions 2022

ASCIA Submissions 2021

ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.

  • ASCIA response to National Blood Authority (NBA) call for public comments on the draft Acute Transfusion Reaction Guidelines. Lodged online 2 July 2021.

Read more …ASCIA Submissions 2021

ASCIA Submissions 2020

ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.

  • ASCIA Immunodeficiency Strategy for Australia and New Zealand. Completed November 2020 and lodged as an attached to the ASCIA submission to the Parliamentary Inquiry 3 November 2020. 

    www.nationalimmunodeficiencystrategy.org.au/

  • Joint letter from ASCIA, National Allergy Strategy, A&AA and CFAR to the Minister for Health (Hon Greg Hunt MP), in response to Recommendation 1 in the Report on the Parliamentay Inquiry into Allergies and Anaphylaxis. Submitted 30 June 2020. pdfJoint letter to Minister Hunt 30-06-20100.27 KB

Read more …ASCIA Submissions 2020

More Articles …